Security key
89357L501
Transcode Therapeutics, Inc. - Common Stock (RNAZ)
CUSIP: 89357L501
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 20
- Total 13F value
- $33
- Share change
- +8
- SEC-reported price per share
- $1.65
- Number of holders
- 2
- Value change
- +$13
- Number of buys
- 1
- Shares outstanding
- 16,846,819
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
2
Top holders
2
RNAZ full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q2 2026
Transcode Therapeutics, Inc. SEC filings
Transcode Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 89357L501
Recent filing periods:
Ownership snapshot
Top reported holders of RNAZ - Transcode Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CK Life Sciences Intl (Ho...
Disclosed value leader
CK Life Sciences Intl (Ho...
Comparable rows
8/15
Latest evidence
09 Sep 2026
13D/G
3/4/5
13F
Lead comparable stake: 84%
7 rows are not safely comparable across share classes.
13D/G row: CK Life Sciences Intl (Holdings) Inc
Showing 1-6 of 15 holder rows.
Quick read
CK Life Sciences Intl (Holdings) Inc leads the comparable SEC ownership view at 84%.
8 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens CK Life Sciences Intl (Holdings) Inc's linked filing trail.
Comparable ownership
Top 5
CK Life Sciences Intl (Holdings) Inc
84%
Unleash Immuno Oncolytics, Inc.
9.9%
YA II PN, Ltd.
9.9%
Elena Rosa Braci
6.2%
Daniel Eduardo Katzman
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CK Life Sciences Intl (Holdings) Inc |
13D/G
3/4/5
CK Life Sciences Int'l., (Holdings) Inc. · 10%+ Owner
|
84%
Reported 13D/G
· 03 Aug 2026
|
$119,295,020
14,134,481 shares
|
$0 | 03 Aug 2026 |
| Unleash Immuno Oncolytics, Inc. |
13D/G
|
9.9%
Reported 13D/G
· 23 Jul 2026
|
$1,875,000
300,000 shares
|
$0 | 23 Jul 2026 |
| YA II PN, Ltd. |
13D/G
|
9.9%
Reported 13D/G
· 15 Apr 2026
|
$35,620
101,772 shares
|
$0 | 15 Apr 2026 |
| Elena Rosa Braci |
13D/G
|
6.2%
Reported 13D/G
· 23 Jul 2026
|
$1,163,975
186,236 shares
|
$0 | 23 Jul 2026 |
| Daniel Eduardo Katzman |
13D/G
|
5.2%
Reported 13D/G
· 23 Jul 2026
|
$972,569
155,611 shares
|
$0 | 23 Jul 2026 |
| Thomas Joseph Tracy |
13D/G
|
5%
Reported 13D/G
· 07 Mar 2025
|
$13,300
35,000 shares
|
$0 | 07 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
20
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
8
Q3 2026 holders
2
Holder diff
-6
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend